Cargando…
P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM).
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430929/ http://dx.doi.org/10.1097/01.HS9.0000970468.19468.a4 |
| _version_ | 1785091077498208256 |
|---|---|
| author | Macro, Margaret Touzeau, Cyrille Mariette, Clara Manier, Salomon Brechignac, Sabine Vincent, Laure Hebraud, Benjamin Decaux, Olivier Schulmann, Samantha Lenoir, Caroline Godmer, Pascal Farge, Agathe Paul, Laure Peyro Saint Parienti, Jean-Jacques Leleu, Xavier |
| author_facet | Macro, Margaret Touzeau, Cyrille Mariette, Clara Manier, Salomon Brechignac, Sabine Vincent, Laure Hebraud, Benjamin Decaux, Olivier Schulmann, Samantha Lenoir, Caroline Godmer, Pascal Farge, Agathe Paul, Laure Peyro Saint Parienti, Jean-Jacques Leleu, Xavier |
| author_sort | Macro, Margaret |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430929 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309292023-08-17 P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM). Macro, Margaret Touzeau, Cyrille Mariette, Clara Manier, Salomon Brechignac, Sabine Vincent, Laure Hebraud, Benjamin Decaux, Olivier Schulmann, Samantha Lenoir, Caroline Godmer, Pascal Farge, Agathe Paul, Laure Peyro Saint Parienti, Jean-Jacques Leleu, Xavier Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430929/ http://dx.doi.org/10.1097/01.HS9.0000970468.19468.a4 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Macro, Margaret Touzeau, Cyrille Mariette, Clara Manier, Salomon Brechignac, Sabine Vincent, Laure Hebraud, Benjamin Decaux, Olivier Schulmann, Samantha Lenoir, Caroline Godmer, Pascal Farge, Agathe Paul, Laure Peyro Saint Parienti, Jean-Jacques Leleu, Xavier P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM). |
| title | P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM). |
| title_full | P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM). |
| title_fullStr | P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM). |
| title_full_unstemmed | P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM). |
| title_short | P891: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RRMM PATIENTS: RESULTS OF THE MULTICENTER PHASE 2 STUDY (IFM 2018-02) OF THE INTERGROUPE FRANCOPHONE DU MYÉLOME (IFM). |
| title_sort | p891: ixazomib and daratumumab without dexamethasone (i-dara) in elderly frail rrmm patients: results of the multicenter phase 2 study (ifm 2018-02) of the intergroupe francophone du myélome (ifm). |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430929/ http://dx.doi.org/10.1097/01.HS9.0000970468.19468.a4 |
| work_keys_str_mv | AT macromargaret p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT touzeaucyrille p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT marietteclara p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT maniersalomon p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT brechignacsabine p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT vincentlaure p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT hebraudbenjamin p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT decauxolivier p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT schulmannsamantha p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT lenoircaroline p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT godmerpascal p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT fargeagathe p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT paullaurepeyrosaint p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT parientijeanjacques p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm AT leleuxavier p891ixazomibanddaratumumabwithoutdexamethasoneidarainelderlyfrailrrmmpatientsresultsofthemulticenterphase2studyifm201802oftheintergroupefrancophonedumyelomeifm |